Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers
NCT03888651
Head and Neck Carcinoma
Houston, Texas, United States
View Trial DetailsNCT Number: NCT05565313
Development and validation of a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Oropharyngeal squamous cell carcinoma (OPSCC) is a rare cancer (incidence ~700 per year in the Netherlands), originating in the middle part of the throat. In OPSCC, nodal status is an important prognostic factor for survival. In the clinical TNM (tumor node metastases) system, nodal status is mainly defined by the size, number and laterality of nodal metastases. In surgically treated patients the pathological TNM classification includes the presence of pathological extranodal extension (pENE). pENE is a predictor for poor outcome and also an indication for the addition of chemotherapy to postoperative radiation. However, most patients with OPSCC are treated non-surgically by means of radiation or chemoradiation and thus information about pENE is lacking. Recently, extranodal extension on diagnostic imaging has been associated with prognosis in OPSCC patients. It is anticipated that in the near future radiological ENE (rENE) may be included in the cTNM classification system for refinement of outcome prediction in patients with nodal disease. The diagnosis of rENE on radiological imaging is new and not trivial and we hypothesize that Artificial Intelligence (AI) may support the radiologist in detecting rENE. In this study we aim to develop and validate a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
The performance of the model will be evaluated in terms of discrimination through the Harrell's C-index and the area (AUC) under the receiver operator curve (ROC) in predicting rENE.
Time frame: 5 years
Percentage of people who are alive five years after their diagnosis.
Time frame: 5 years
Percentage of people whp who are disease free five years after their diagnosis.
This study is active but is not currently recruiting participants.
Notify MeMaastricht Radiation Oncology
Other
Acronym: AI4rENE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03888651
Head and Neck Carcinoma
Houston, Texas, United States
View Trial DetailsNCT02465060
Adenocarcinoma, Adnexal Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04147494
Adenocarcinoma, Adnexal Diseases
Los Angeles, California, United States
View Trial DetailsNCT03612531
Cancer Survivor, Deglutition Disorders
Houston, Texas, United States
View Trial Details